Thermo Fisher Scientific (NYSE:TMO) PT Raised to $660.00 at HSBC

Thermo Fisher Scientific (NYSE:TMO) had its target price raised by equities research analysts at HSBC from $630.00 to $660.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the medical research company’s stock. HSBC’s price target indicates a potential upside of 21.82% from the company’s current price.

TMO has been the subject of several other reports. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Royal Bank of Canada boosted their price objective on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Barclays lowered Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and boosted their target price for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Finally, Evercore ISI boosted their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a research report on Thursday, April 4th. Five analysts have rated the stock with a hold rating and twelve have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $604.69.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock opened at $541.78 on Wednesday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39. The stock has a fifty day moving average price of $571.39 and a two-hundred day moving average price of $527.11. Thermo Fisher Scientific has a 52-week low of $415.60 and a 52-week high of $603.82. The firm has a market capitalization of $206.80 billion, a P/E ratio of 35.07, a P/E/G ratio of 2.33 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion during the quarter, compared to analyst estimates of $10.73 billion. During the same period last year, the company posted $5.40 earnings per share. The firm’s quarterly revenue was down 4.9% compared to the same quarter last year. As a group, analysts anticipate that Thermo Fisher Scientific will post 21.52 EPS for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the sale, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the sale, the director now owns 1,207 shares in the company, valued at approximately $660,192.79. The disclosure for this sale can be found here. Insiders have sold a total of 50,277 shares of company stock worth $28,513,384 in the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TMO. Northwest Financial Advisors acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth $29,000. True Wealth Design LLC raised its position in Thermo Fisher Scientific by 1,275.0% in the fourth quarter. True Wealth Design LLC now owns 55 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 51 shares during the last quarter. Coppell Advisory Solutions LLC bought a new position in Thermo Fisher Scientific in the second quarter valued at about $33,000. Live Oak Investment Partners bought a new position in Thermo Fisher Scientific in the fourth quarter valued at about $36,000. Finally, Tyler Stone Wealth Management bought a new position in Thermo Fisher Scientific in the second quarter valued at about $37,000. 89.23% of the stock is owned by institutional investors and hedge funds.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.